Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.71 |
| ▸ | NPC1 | O15118 | 7/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | BLVRB | P30043 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | GRM5 | P41594 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12171450 | 1.00 | RAB9A (0.71) | RAB9ANPC1L3MBTL1NR1H4HDAC6 | |
| SCHEMBL59426 | 0.89 | NPC1 (0.67) | RAB9ANPC1L3MBTL1NR1H4HDAC6 | |
| SCHEMBL4871450 | 0.89 | NR1H4 (0.68) | RAB9ANPC1L3MBTL1NR1H4HDAC6 | |
| SCHEMBL19131261 | 0.89 | NPC1 (0.66) | RAB9ANPC1L3MBTL1NR1H4SMN1; SMN2 | |
| SCHEMBL60427 | 0.87 | NPC1 (0.76) | RAB9ANPC1L3MBTL1NR1H4HDAC6 | |
| SCHEMBL12171569 | 0.87 | NPC1 (0.76) | RAB9ANPC1L3MBTL1NR1H4HDAC6 | |
| SCHEMBL13882259 | 0.85 | RAB9A (0.77) | RAB9ANPC1L3MBTL1SMN1; SMN2TP53 | |
| SCHEMBL19131262 | 0.84 | NR1H4 (0.77) | RAB9ANPC1L3MBTL1NR1H4HDAC6 | |
| SCHEMBL59247 | 0.84 | RAB9A (0.72) | RAB9ANPC1L3MBTL1NR1H4HDAC6 | |
| SCHEMBL940686 | 0.84 | NR1H4 (0.69) | RAB9ANPC1L3MBTL1NR1H4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9205088-B2 | Compositions of 1,2,4-oxadiazol benzoic acid compounds and methods for their use | PTC THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | claimed |
| US-20150148346-A1 | COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE | PTC THERAPEUTICS INC. (US) | 2015-05-28 | — | — | US | claimed |
| US-8486982-B2 | 1,2,4-oxadiazole benzoic acids | PTC THERAPEUTICS, INC. (US) | 2013-07-16 | — | — | US | claimed |
| US-20120277234-A1 | 1,2,4-OXADIAZOLE BENZOIC ACIDS | PTC THERAPEUTICS, INC. | 2012-11-01 | — | — | US | claimed |
| US-8227494-B2 | Pharmaceutical compositions of 1,2,4-oxadiazole benzoic acid and their use for the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2012-07-24 | — | — | US | claimed |
| US-6992096-B2 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. (US) | 2006-01-31 | — | — | US | claimed |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. | 2004-10-14 | — | — | US | claimed |
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4101846-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4101846-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-3889142-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-3889142-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20060148864-A1 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060035943-A1 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | PTC THERAPEUTICS, INC. | 2006-02-16 | — | — | US | disclosed |
| US-6992096-B2 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| EP-1618098-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PCT Therapeutics Inc. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050164973-A1 | E.g., 3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay | PCT THERAPEUTICS, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2004091502-A2 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | PTC THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277234-A1 | 1,2,4-OXADIAZOLE BENZOIC ACIDS | UPF1, RIOX2, RPL35A | RAB9A 3978/4885NPC1 1568/4885L3MBTL1 105/4885 |
| US-20150148346-A1 | COMPOSITIONS OF 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND METHODS FOR THEIR USE | UPF1, RIOX2, RNMT | RAB9A 4327/4885NPC1 1473/4885L3MBTL1 195/4885 |
| US-20060148864-A1 | Treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | UPF1, PABPC1, PABPC4 | RAB9A 3213/4885NPC1 1001/4885L3MBTL1 51/4885 |
| US-20060035943-A1 | E.g., 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid; treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay such as genetic disorders | UPF1, PABPC1, PABPC4 | RAB9A 3420/4885NPC1 1558/4885L3MBTL1 42/4885 |
| US-20050164973-A1 | E.g., 3-[5-(4-Fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid; treating diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay | UPF1, PABPC1, PABPC4 | RAB9A 2955/4885NPC1 908/4885L3MBTL1 107/4885 |
| US-20040204461-A1 | translation of mRNA is allowed to continue past a nonsense mutation point, resulting in the production of a full length protein; genetic disorders; 3-(5-p-tolyl-[1,2,4]oxadiazol-3-yl)-benzoic acid | UPF1, PABPC1, PABPC4 | RAB9A 3331/4885NPC1 2171/4885L3MBTL1 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.